|Awarded On||August 16, 2017|
|Title||Targeting Cathepsin L as a Selective Mechanism for the Release of Potent Anticancer Agents from Drug-Linker Conjugates|
|Award Mechanism||High Impact/High Risk|
|Principal Investigator/Program Director||Kevin G Pinney|
The discovery and development of new, targeted therapeutic regimens for the treatment of cancer is crucial for realization of the promise afforded by the future of precision oncology. Pancreatic cancer is among the most deadly cancers in which patient survival is low and treatment options remain limited. In this proposal, the synthesis and biological evaluation of drug-linker conjugates is described that are designed to be activated (cleaved) by a specific enzyme (cathepsin L) that is found in increasingly high levels in and around pancreatic cancer cells as the disease progresses. Cleavage of these drug-linker conjugates will release very potent, small-molecules that were discovered by the ...